Given its rare occurrence, there is no consensus yet on the appropriate management of polyclonal (i.e., multiple) primary tumors with competing targetable mutations, and further studies are warranted to optimize the treatment strategies for synchronous lung cancers presenting with concomitant EGFR mutation and ALK translocation, reflecting the intricacies required for a more promising tailored approach for lung cancer patients. Here, ALK is linked to lung carcinoma.